Modification of COPD presentation during the last 25 years

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 7, Issue 5, 2010, Pages 345-351

  Fremault, Antoine ^a   Janssens, Wim ^a   Beaucage, François ^a   Celis, Geert ^a   Pérez Bogerd, Silvia ^a   Decramer, Marc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

COPD; exacerbations; phenotype; systemic consequences

Indexed keywords

HEMOGLOBIN;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL;

AGED; BELGIUM; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 77956970385     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2010.510546     Document Type: Article

References (29)

1. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003 May; 123(5):1684-1692.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004 Aug 14; 364(9434):613-620.
3. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006 Jan; 27(1):188-207.
4. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997 May 3; 349(9061):1269-1276.
5. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007 Sep 1; 370(9589):797-799.
6. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57(10):847-852.
7. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 Jun 25; 1(6077):1645-1648.
8. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356(8):775-789.
9. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 Oct 9; 359(15):1543-1554.
10. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al. Effect of Pharmacotherapy on Rate of Decline of Lung Function in COPD: Results from the TORCH Study. Am J Respir Crit Care Med 2008; 178:332-338.
11. van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008 Jul 15;102(2):192-196.
12. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, deMolina RM, Nakashima B, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009 Jun 3;10:45.
13. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Betablockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010 May 24; 170(10):880-887.
14. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD)Workshop summary. Am J Respir Crit Care Med 2001 Apr; 163(5):1256-1276.
15. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003 Aug; 124(2):459-467.
16. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined co-morbidity index. J Clin Epidemiol 1994 Nov; 47(11):1245-1251.
17. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of co-morbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008 Jun; 63(6):487-492.
18. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993 Mar; 16:5-40.
19. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med 2007 Mar 1; 175(5):458-463.
20. Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M. Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med 2009 Apr 15; 179(8):630-636.
21. Franssen FM, O Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. Thorax 2008 Dec; 63(12):1110-1117.
22. Zanobetti A, Bind MA, Schwartz J. Particulate air pollution and survival in a COPD cohort. Environ Health 2008 Oct 10; 7:48.
23. Brown DW, Croft JB, Greenlund KJ, Giles WH. Average age at death from COPD in the United States: 1980-1985, 1990-95, 2000-05. COPD 2009 Jun; 6(3):152-154.
24. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009 Nov 15; 180(10):948-955.
25. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002 Aug 1; 166(3):333-339.
26. Braman SS, Lee DW. Primary care management of chronic obstructive pulmonary disease: an integrated goal-directed approach. Curr Opin Pulm Med 2010 Mar; 16(2):83-88.
27. Gross N, Levin D. Primary care of the patient with chronic obstructive pulmonary disease-part 2: pharmacologic treatment across all stages of disease. Am J Med 2008 Jul; 121(7 Suppl):S13-S24.
28. Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G, Vassilakos P, et al. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 1999 Feb; 106(2):158-164.
29. Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, Hruska N, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006 May; 27(5):972-979.